Welcome to the latest edition of European Neurological Review, which features a diverse range of topical articles covering a variety of therapeutic areas. This edition begins with a timely editorial from Milonas on recent advances in multiple sclerosis (MS), which is also the subject of two other articles. Kesselring discusses the concept of neurorehabilitation in MS, while Vermesch presents a review of teriflunomide, an immunotherapy agent whose oral administration should help establish its role within the increasing number of therapeutic options for MS.
Our understanding of Parkinson’s disease (PD) has evolved in recent years following advances in our understanding of the pathological processes involved. Titova, Jenner and Chaudhuri discuss how this enhanced understanding will impact on the future treatment of PD, particularly in regard to personalised medicine.
Around 30% of patients with epilepsy are, or will become, refractory to treatment with available antiepileptic drugs. As a result, there remains a need for new and effective treatments. In a review article, Trinka and Carreňo discuss the use of perampanel, a novel therapeutic agent that blocks the action of glutamate at α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the brain and has recently been approved for the treatment of patients with epilepsy. However, reimbursement is not secured in some European countries, and there is an ongoing debate as to whether there is really additionally benefit from perampanel for epilepsy patients in general.
Finally, we feature two articles on the subject of headache disorders. Silva-Néto and Soares present a literature review of the intriguing relationship between odours and primary headaches, which could have important implications for the diagnosis of migraine and gives more insight into the pathophysiology of migraine. In addition, Karsan and Goadsby review current understanding of the neurobiology of the premonitory-like symptoms, such as tiredness, concentration impairment, memory impairment and mood change, which start before pain.
European Neurological Review would like to thank all authors who contributed their expertise to this edition. We would also like to thank all the members of our editorial board for their ongoing support and guidance. We hope that readers enjoy these articles and that they prove to be thought-provoking and useful.
